After a long period without face to face contact, we were delighted to host a diverse and distinguished group for our inaugural cell and gene summit. It provided an invaluable opportunity for industry leaders to collaborate and discuss the biggest challenges facing our sector today. Events such as this are vital for building and growing a strong cell and gene therapy ecosystem in Cambridge and beyond. We are incredibly fortunate to have so many of the vital ingredients concentrated in a small area. By combining ground breaking therapies, innovative technologies and manufacturing capacity the UK innovation corridor is at the heart of driving these therapies forward and bringing cell and gene therapies into mainstream medicine. I am convinced that only by working together as a community will we succeed in getting these life changing therapies to patients.
UK Innovation corridor ‘critical’ to development of cell and gene therapy, TTP plc summit told
- TTP plc hosted the first cell and gene therapy summit at its Melbourn HQ.
- “Events such as this are vital for building and growing a strong cell and gene therapy ecosystem in Cambridge and beyond” say TTP.
TTP plc hosted the first cell and gene therapy summit at its Melbourn HQ.
“Events such as this are vital for building and growing a strong cell and gene therapy ecosystem in Cambridge and beyond” say TTP.
Cambridge, UK, 30 September 2021: Experts, business leaders and researchers from over 30 companies convened at the HQ of TTP plc on Wednesday 15th September for its first ever Cell and Gene Therapy (CGT) Summit.
The event, which was organised and hosted by TTP plc – a leading independent UK technology and product development company – saw leading professionals from the Cambridge area and beyond come together to explore how the industry can grow the UK’s position as a leader of CGT development.
Panellists highlighted the critical role that the UK’s Innovation Corridor, the leading sci-tech region between London and Cambridge, can play in fostering and supporting the industry as it matures from early stage discovery to the exploration of commercial viability and manufacturing.
In a day of wide-ranging discussions, speakers from Achilles Therapeutics, Aglaris, AstraZeneca, GammaDelta Therapeutics, and Mogrify highlighted existing barriers that prevent the successful delivery of cell and gene therapies.
During a panel session hosted by Kath Mackay, Director of Life Sciences, Bruntwood SciTech, speakers identified greater collaboration, diversity and continued government investment as crucial components which will support the UK’s continued leadership in this field.
Meanwhile, Kasia Averall, Head of Cluster Development, Cell and Gene Therapy Catapult, emphasized the importance of providing infrastructure and expertise to help start-ups and scale-ups to progress towards large-scale manufacture and commercialisation of their therapies at reduced risk.
Reflecting on the event, Edwin Stone, Head of Cell and Gene Therapy at TTP said:
To find out more about TTP Cell and Gene Therapy visit: ttp.com/cell-and-gene-therapy
